P109 Efficacy and safety of a 3-monthly depot formulation of degarelix compared with goserelin in prostate cancer

Autor:	Laurence Klotz, Bertrand Tombal, B.E. Persson, T. Tammela, E.D. Crawford, M.C. Gittelman, J.M. Wolff, Neal D. Shore, Tine Kold Olesen, Heather Payne
Rok vydání:	2012
Předmět:	Oncology medicine.medical_specialty business.industry Depot Urology Goserelin medicine.disease Prostate cancer chemistry.chemical_compound chemistry Internal medicine medicine Degarelix business medicine.drug
Zdroj:	European Urology Supplements. 11:228
ISSN:	1569-9056
DOI:	10.1016/s1569-9056(13)60476-5
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::57d1e61274501ca0b61c946ec0622e7a https://doi.org/10.1016/s1569-9056(13)60476-5 Zobrazit plný text záznamu Full Text from ScienceDirect